ArticleFrontiers in immunology2026
Familial patterns of immune dysregulation in CVID: insights from B- and T-cell phenotyping and antibody profiling.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Common Variable Immunodeficiency (CVID) is a heterogeneous immune disorder characterized by a broad range of clinical manifestations. Its etiology is not yet fully understood. To gain insights into the immunological background of CVID in patients without a clearly defined genetic cause, we employed a genealogical research approach that included family members. This strategy aims to provide a more comprehensive understanding of immune dysregulation in CVID, of potential hereditary patterns, and subclinical immunological traits within families. Methods: Fifty-eight participants from nine families were included: Five families with a negative family history for CVID (FH-) and four families with a positive family history for CVID (FH+). Screening for known CVID-associated genes was negative in all cases. The non-affected family members completed a questionnaire covering medical history relevant to primary immunodeficiency. Flow cytometry was used to analyze T- and B-cell subsets in peripheral blood, while mucosal and systemic IgA and IgG levels were measured using a multiplex immunoassay. Results: Immune aberrancies in CVID patients were observed in the B- and T-cell compartments. In both FH- and FH+ family members, symptoms suggestive of Primary Immunodeficiency (PID) were present in 32.1 to 61.5% (p = 0.29). B-cell subsets were 5- to 10-fold reduced compared with the 5th percentile of age specific reference values. A combination of T-cell and B-cell reductions was observed in eight of the nine families in a non-affected member. Serum and mucosal IgG and IgA levels in FH- families did not differ significantly from FH+ families. There were no significant correlations between systemic and mucosal IgA levels in non-affected family members from either FH- or FH+ families. Conclusion: Overall, our findings show that B- and T-cell aberrancies are present not only in CVID patients but also in non-affected family members, irrespective of family history. Systemic IgA does not reflect mucosal IgA, and systemic IgG replacement therapy does not restore mucosal antibody levels, highlighting compartmentalized immune regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.